Literature DB >> 27057403

A Case of Wernicke-Korsakoff Syndrome Treated 1 Year After the Onset of Symptoms.

Rabia Bilici1, Gokce Elif Saridogan1, Cetin Turan1, Tugba Goncu1, Ozgur Akdur1, Serhat Citak1, Fusun Mayda Domac1.   

Abstract

Entities:  

Year:  2015        PMID： 27057403      PMCID： PMC4805404          DOI： 10.4088/PCC.15l01801

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  7 in total

1.  Complete recovery from undertreated Wernicke-Korsakoff syndrome following aggressive thiamine treatment.

Authors:  Thomas Paparrigopoulos; Elias Tzavellas; Dimitris Karaiskos; Anastasios Kouzoupis; Ioannis Liappas
Journal:  In Vivo       Date:  2010 Mar-Apr       Impact factor: 2.155

2.  EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy.

Authors:  R Galvin; G Bråthen; A Ivashynka; M Hillbom; R Tanasescu; M A Leone
Journal:  Eur J Neurol       Date:  2010-12       Impact factor: 6.089

Review 3.  Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management.

Authors:  Gianpietro Sechi; Alessandro Serra
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

Review 4.  B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse.

Authors:  C C Cook; P M Hallwood; A D Thomson
Journal:  Alcohol Alcohol       Date:  1998 Jul-Aug       Impact factor: 2.826

Review 5.  Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders.

Authors:  N Latt; G Dore
Journal:  Intern Med J       Date:  2014-09       Impact factor: 2.048

Review 6.  Neuroimaging of the Wernicke-Korsakoff syndrome.

Authors:  Edith V Sullivan; Adolf Pfefferbaum
Journal:  Alcohol Alcohol       Date:  2008-12-09       Impact factor: 2.826

Review 7.  The Korsakoff syndrome: clinical aspects, psychology and treatment.

Authors:  Michael D Kopelman; Allan D Thomson; Irene Guerrini; E Jane Marshall
Journal:  Alcohol Alcohol       Date:  2009-01-16       Impact factor: 2.826
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.